You are here: Industry Insights > PAD

News List

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment PRNewswire
January 07, 2025
how that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD).
12-Month Below-the-Knee Data with MedAlliance's SELUTION SLR? Presented as Late Breaking Trial at LINC europeanpharmaceuticalreview
January 29, 2021
12-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021.
MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head Trial Comparing Wynzora? Cream to Daivobet? Gel in Patients with Psoriasis b3cnewswire
December 25, 2019
MC2 Therapeutics, an emerging pharmaceutical company focused on novel?PAD? Technology?based topical therapies for chronic inflammatory conditionss, announced that its EU Phase 3 trial (n=490) on the company’s investigational drug ...
Poor Circulation in Legs? Statin Meds Can Keep You Living Longer drugs
September 05, 2019
Folks with peripheral artery disease (PAD) have a much lower risk of death if they take cholesterol-lowering statins as directed by their doctor, a new study reports.
Smoking Creates Long-Lasting Risk for Clogged Leg Arteries drugs
August 06, 2019
Cigarette smokers have a sharply higher risk of peripheral artery disease (PAD) -- and even if they quit, that added risk can last for decades, a new study warns.
Online Symptom Self-Management + Telehealth Aids Pain, Mood drugs
July 29, 2019
Online symptom self-management plus clinician telecare can be effective for individuals with pain, depression, and anxiety...
FDA Issues Update on Mortality Risk With Paclitaxel-Coated Products drugs
March 19, 2019
?A preliminary analysis has revealed a "potentially concerning signal" of increased long-term mortality risk with paclitaxel-coated products indicated for peripheral arterial disease (PAD), according to a March 15 update from the U.S. Food and Drug Admini